Oragenics Inc (OGEN)

May 05, 2026

Oragenics, Inc. Opens Second Clinical Site for Phase IIa Trial of ONP-002, Evaluating Treatment for Concussion with 60 Participants - geneonline.com

May 05, 2026

May 05, 2026

Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site - citybuzz -

May 05, 2026

May 05, 2026

Oragenics adds second site to concussion drug trial in Australia - Investing.com

May 05, 2026

May 05, 2026

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - GlobeNewswire

May 05, 2026

Apr 27, 2026

Oragenics shares plunge following announcement of $20 million preferred stock sale - MSN

Apr 27, 2026

Apr 24, 2026

OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill

Apr 24, 2026

Apr 20, 2026

Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Trea - GuruFocus

Apr 20, 2026

Apr 20, 2026

Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Treatment - GuruFocus

Apr 20, 2026

Apr 20, 2026

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - The Manila Times

Apr 20, 2026

Apr 20, 2026

Concussion has no approved drug; Oragenics doses 2 in trial - Stock Titan

Apr 20, 2026

Apr 17, 2026

OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill

Apr 17, 2026

Apr 15, 2026

OGEN Ownership | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill

Apr 15, 2026

Apr 13, 2026

Earnings Recap: Is Oragenics Inc gaining market shareWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment - citybuzz -

Apr 13, 2026

Apr 13, 2026

Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia - TipRanks

Apr 13, 2026

Apr 13, 2026

Oragenics Doses First Patient in Phase IIa Trial of ONP-002 for Concussion, Targeting Unmet Need in Mild Traumatic Brain Injury 1 - Minichart

Apr 13, 2026

Apr 13, 2026

Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion - TradingView

Apr 13, 2026

Apr 13, 2026

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewswire

Apr 13, 2026

Apr 11, 2026

Sectors Review: Is Oragenics Inc stock technically oversold2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Oragenics (OGEN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat

Apr 10, 2026

Apr 09, 2026

Nasdaq Moves: Is Oragenics Inc vulnerable to short sellersQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Risk On: Is Oragenics Inc gaining market sharePrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Rally Mode: Is Oragenics Inc gaining market share2026 Trading Volume Trends & Long-Term Capital Growth Strategies - baoquankhu1.vn

Apr 09, 2026

Apr 06, 2026

Can Oragenics (OGEN) Stock Rebound in 2026 | Price at $0.61, Up 8.48%Risk Management - Newser

Apr 06, 2026

Apr 04, 2026

0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada

Apr 04, 2026

Apr 03, 2026

Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - ca.finance.yahoo.com

Apr 03, 2026

Apr 01, 2026

Oragenics Sets New 2025 Annual Shareholder Meeting Date - The Globe and Mail

Apr 01, 2026

Mar 31, 2026

Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget

Mar 31, 2026

Mar 31, 2026

Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan

Mar 31, 2026

Mar 29, 2026

Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn

Mar 29, 2026

Mar 26, 2026

Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -

Mar 26, 2026

Mar 26, 2026

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - Sahm

Mar 26, 2026

Mar 25, 2026

Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus

Mar 25, 2026

Mar 25, 2026

OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 25, 2026

Mar 23, 2026

Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 23, 2026

Mar 23, 2026

[EFFECT] ORAGENICS INC SEC Filing - Stock Titan

Mar 23, 2026

Mar 23, 2026

If You Invested $1,000 in Oragenics (OGEN) - Stock Titan

Mar 23, 2026

Mar 22, 2026

Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 22, 2026

Mar 20, 2026

Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com

Mar 20, 2026

Mar 20, 2026

OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill

Mar 20, 2026

Mar 19, 2026

Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan

Mar 19, 2026

Mar 17, 2026

Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -

Mar 17, 2026

Mar 17, 2026

Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com

Mar 17, 2026

Mar 17, 2026

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times

Mar 17, 2026

Mar 16, 2026

Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 16, 2026